INTRODUCTION
Early HIV infection (EHI) is the period from HIV acquisition through the establishment of chronic infection. EHI encompasses the eclipse phase (when HIV is not detectable in the plasma) [1] , acute HIV infection (AHI) (when HIV is detectable, but the antibody response is not), and recent infection (when HIV antibodies are detectable by sensitive diagnostic assays, but the immune response is immature). Together these phases last approximately 3-6 months. EHI ends when a stable viral 'set point' is established, a key determinant of subsequent disease progression [2] and chronic transmissibility. Directed laboratory testing can locate individuals within this spectrum. One common system proposed in 2003 by Fiebig et al.
[1] defined six EHI stages on the basis of the maturation of viremia and antibody responses using then-current diagnostics. With substantial advances in EHI diagnostics, efforts are now underway to improve on this staging system [3 && ]. At the individual level, EHI detection is important for proper diagnosis. When EHI clinical manifestations occur, they are almost universally misdiagnosed as another endemic illness, such as malaria or influenza, resulting in inappropriate subsequent testing and treatment [4,5 && ,6]. More rarely, severe manifestations of EHI, such as meningitis, encephalitis, or esophagitis, can occur, which must be distinguished from both non-HIV causes and manifestations of AIDS.
EHI detection is also important for infection management. Detecting and correctly staging EHI enables rapid initiation of treatment with potential for long-term clinical benefits [7, 8 changes occur over the first few weeks of infection: irreversible depletion of CD4 lymphocytes in the gut [9] , mucosal damage allowing gastrointestinal bacterial products access to the circulation [ In this review, we discuss the markers of EHI, strategies for detecting these markers, and how these strategies have been combined into algorithms for individual EHI case detection and HIV incidence estimation.
CLINICAL MARKERS OF ACUTE HIV INFECTION
During the first several weeks of HIV infection, many persons display an acute retroviral syndrome with symptoms, such as fever, diarrhea, and rashes [29] . Because these symptoms are nonspecific, they cannot reliably identify AHI independently. 
DETECTION OF ACUTE VIREMIA (PREANTIBODY PHASE)
HIV RNA and p24 antigen, components of circulating virions in plasma, are detectable before HIV antibodies are formed (Fig. 1) . HIV RNA appears first, approximately 7-10 days after HIV infection, and can be detected using PCR or other nucleic acid amplification technologies (NAATs). Currently, RNA testing is performed in well resourced laboratories. Samples can be tested individually, or
KEY POINTS
In the USA and Europe, laboratory-based diagnostic algorithms increasingly incorporate fourth-generation HIV antigen tests, allowing for earlier HIV detection.
In some sub-Saharan African settings, symptom-based screening has been explored to identify subsets of persons at high risk for AHI.
Point-of-care diagnostics designed for AHI detection are in the pipeline and, if validated, represent an exciting opportunity for diagnosis in real time.
MAAs are a promising new strategy for estimating HIV incidence at the population level.
multiple samples can be tested at once in 'pools,' with only samples from positive pools subsequently tested individually [36, 37] . Optimal pooling strategies for different conditions have been described [38] with substantial reductions in cost, but with increases in time and complexity. The next biomarker to appear is p24 antigen, which is detectable approximately 5-7 days after HIV RNA. P24 can be detected by 'fourth-generation', antigen-antibody 'combo' assays with very good performance characteristics [39 & ,40,41] . Fourth-generation laboratory immunoassays have become routine in European countries and have replaced HIV antibody-only tests for HIV screening in many US laboratories [42] . Unfortunately, neither fourth-generation laboratory immunoassays nor traditional HIV NAATs are suitable for rapid, point-of-care diagnosis in the clinic settings in which AHI is common and the potential for efficient AHI case-finding the greatest.
Notably, two first-generation rapid NAAT devices for use in AHI diagnosis have been introduced quite recently. The Alere q HIV-1/2 Detect (Alere Technologies, Jena, Germany) is designed for both point-of-care early infant diagnosis and potentially adult AHI diagnosis. The first assessment shows excellent performance characteristics in infants [43 ] , but field test results for adult AHI are not available. The SAMBA HIV semiquantitative pointof-care test was developed primarily for point-ofcare viral load monitoring, and secondarily to detect persons with AHI, but to date it has not been evaluated for AHI either [44 & ]. Previous efforts to deploy rapid tests for AHI have been mixed: the Alere Determine HIV-1/ 2 Ag/Ab is a lateral flow-based rapid test designed to detect and differentiate established HIV infection (through detection of HIV antibodies) and EHI (through detection of p24 antigen) at the point of care using plasma, serum, or whole blood. The 
DETECTING POSTANTIBODY EARLY HIV INFECTION
Approximately 1 week after the appearance of p24, immunoglobulin M antibodies are detectable through third-generation immunoassays, several weeks earlier than first or second-generation immunoassays. Although third-generation assays detect HIV earlier, they classify very few persons with EHI when used in combination with fourth-generation assays, due to the very brief 'window period.' Identifying persons with EHI in the postseroconversion period is also important, as it allows for brief early interventions for treatment or prevention.
In the past, results from supplemental western blot tests extended the EHI period by several weeks, and could be used to stage persons in the early postseroconversion period [61] . However, the western blot is no longer being performed in most clinical laboratories. Among confirmatory tests replacing the western blot are the INNO-LIA HIV I/II Score (Innogenetics, Gent, Belgium) [62] and a newer rapid test, the Bio-Rad Geenius HIV 1/2 Assay (Bio-Rad Laboratories, Inc.). These diagnostics provide similar semiquantitative information and can distinguish EHI from long-standing infections [55,63 & ] if such information is sought. Updated staging systems, which rely on diagnostics currently in use, are urgently needed.
Additional assays rely on the evolving nature of the antibody response following HIV acquisition with respect to quantity, proportion, avidity, or isotope. These antibody-testing approaches, referred to as 'incidence assays' because of their use in HIV surveillance, have been developed to classify EHI among antibody-positive individuals. These include the serologic testing algorithm for recent seroconversion, the BED capture enzyme immunoassay (BED-CEIA), and limiting-antigen (LAg) avidity assays (discussed in more detail below).
Genetic information can also be used to stage EHI. Within a single host, the HIV genome is typically homogenous following acquisition and diversifies over time into complex quasispecies, making viral diversity another potential measure of EHI duration. Some of these methods include 'molecular clock' models [64], high-resolution melting technologies implemented manually or through automated platforms [65] [66] [67] 68 && ], HIV sequencing techniques [69] , and Pairwise Alignment Positional Nucleotide Counting, a novel computational method [70 && ,71] . These assays are currently used for research purposes and some have been incorporated into HIV incidence estimation activities.
EVOLVING PRACTICE IN EARLY HIV INFECTION DETECTION AND STAGING
In 2014, nearly all well resourced countries have adopted fourth-generation immunoassays as firstline screening tests for HIV, on a variety of automated and manual platforms. In 2014, the Centers for Disease Control and Prevention (CDC) issued a new laboratory algorithm for use in the USA with a sequence of US FDA-approved HIV assays designed to detect persons in either EHI or chronic HIV infection, and to differentiate HIV-1 from HIV-2 [72, 73, 74 && ] (Fig. 2) . The algorithm begins with a highly sensitive fourth-generation test, and, for reactive samples, an immunoglobulin G immunoassay capable of differentiating HIV-1 from HIV-2. Antibody-nonreactive specimens can be tested individually for HIV-1 RNA to identify patients who were recently infected. Use of fourth-generation and NAAT technology has increased detection of AHI in US settings where this has been implemented [36, 75, 76 & -79 & ]. In many European countries, including the United Kingdom, France, and Italy, modified 'incidence assays' are used routinely to complete the staging of new infections as being in EHI versus long-standing HIV infection. Assay results are provided to guide patient management, in addition to the information they contribute to surveillance. In the USA, negative, indeterminate, or evolving results of supplemental antibody tests are often used to make the diagnosis of EHI, but the use of supplemental incidence assays has not been embraced. In 2014, however, the US CDC issued a new surveillance case definition, which, for the first time, includes EHI as a reportable category referred to as 'stage 0' HIV infection [80 && ]. This guideline, along with the arrival of new supplemental assays capable of EHI staging, may lead to more postseroconversion EHI diagnosis in the USA.
EVOLVING PRACTICE IN HIV INCIDENCE ESTIMATION
HIV incidence estimation, which also relies on the detection of EHI, can be measured directly in cohorts of HIV-uninfected persons followed longitudinally for HIV seroconversion. However, longitudinal methods require large cohorts, followed at frequent intervals, over long periods with minimal, nondifferential loss to follow-up [81] . Additionally, the process of frequent HIV testing can itself affect HIV acquisition risk [82] .
Back-projection techniques were developed for incidence estimation in surveillance data, using assumptions about the timing between HIV acquisition and HIV testing. However, due to inevitable time lags, these techniques were inadequate for measuring recent trends, and estimates were often imprecise due to assumptions about the duration between infection and diagnosis [83] [84] [85] [86] .
Cross-sectional HIV incidence estimation can measure recent HIV incidence trends with one or more biomarker at a single time point. The Serologic Testing Algorithm for Recent Seroconversion relies on the maturity of the antibody response [87, 88] , but variability between HIV subtypes makes this approach unreliable [89, 90] . The BED-CEIA was designed to detect multiple HIV-1 subtypes and differentiate recent from long-standing seroconversion based on the proportion of anti-HIV immunoglobulin G, but misclassifies persons with advanced disease and immunosuppression as having EHI, leading to overestimates [91] [92] [93] [94] . The newer LAg assay measures the avidity of antibody binding to low concentrations of a multisubtype peptide derived from an immunodominant region of gp41 [95, 96] . However, this assay suffers from similar challenges of misclassifying persons with advanced HIV disease, elite controllers, and persons with viral suppression and partial seroreversion following ART as having EHI [ 
CONCLUSION
Careful study of the natural history of EHI has resulted in an array of clinical, virologic, immunologic, and genetic markers that can be used to identify EHI cases and classify them into different stages. The brevity of each stage and the difficulty to identify them and distinguish them from established HIV infection at the point of care remain major challenges. Nonetheless, substantial progress has been achieved at the individual and population levels. As more persons with prevalent HIV infection learn their HIV status, a larger share of those in need of HIV diagnosis will be those with EHI, making its detection increasingly important. Ever better strategies for simple, efficient detection of EHI and measurement of HIV incidence are critical public health priorities.
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